Abstract: Excessive sleepiness (ES) is responsible for signifi cant morbidity and mortality due to its association with cardiovascular disease, cognitive impairment, and occupational and transport accidents. ES is also detrimental to patients' quality of life, as it affects work and academic performance, social interactions, and personal relationships. Armodafi nil is the R-enantiomer of the established wakefulness-promoting agent modafi nil, which is a racemic mixture of both the R-and S-enantiomers. R-modafi nil has a longer half-life and is present at higher circulating concentrations than the S-enantiomer following chronic administration of modafi nil and may therefore be the enantiomer predominantly responsible for the benefi cial effects of the racemic compound. Armodafi nil has been approved by the Food and Drug Administration for the improvement of ES associated with narcolepsy, shift-work disorder, and obstructive sleep apnea following a program of randomized, placebo-controlled clinical trials. This comprehensive medication review discusses the pharmacologic profi le of armodafi nil and the current evidence regarding its effi cacy, safety, and tolerability; appraises patient-reported outcomes data; and suggests additional indications in which armodafi nil may be of use.
Introduction
Excessive sleepiness (ES) is drowsiness that occurs at inappropriate times and may happen for myriad reasons including insuffi cient sleep (due to insomnia or poor sleep habits), interrupted sleep (as experienced by patients with obstructive sleep apnea [OSA]), neurologic disorders (e.g. narcolepsy, dementing illnesses, or stroke), sleep-timing issues (e.g. the circadian rhythm disorders shift-work disorder [SWD] and jet lag), and side effects from pharmacologic agents (such as some antidepressants and pain medications).
A dramatic example of ES associated with OSA occurred in February 2008 when a regional jet overfl ew its destination on a regularly scheduled mid-morning fl ight between the Pacifi c islands of Oahu and Hawaii. Go! fl ight 1002 left Honolulu airport at 0916 hours without incident. When the Hilo air-traffi c controller radioed the aircraft with landing instructions only 24 minutes later, neither the 23-year-old fi rst offi cer nor the 53-year-old captain responded. Go! fl ight 1002 fl ew past the Kona airport and continued over the Pacifi c Ocean for 18 minutes for a distance of approximately 26 miles before the pilots fi nally awoke and responded. The captain reported that he often intentionally napped during fl ights and was subsequently found to have OSA. 1 ES is associated with signifi cant morbidity and mortality, independent of accompanying conditions. For example, ES has been linked with a greater risk of developing cardiovascular disease and death from cardiovascular disease 2 ; a recent study has reported that this is not as a result of coronary artery calcification. 3 There is some evidence, however, that ES is implicated in hypertension, which could be involved in the pathology of heart disease in these patients. 4 For example, ES may promote hypertension in patients with OSA, as patients with OSA and ES who are treated effectively for these conditions experience reductions in blood pressure, while those with OSA in the absence of ES do not experience reductions in blood pressure. [5] [6] [7] [8] One possible mechanism for ES-related hypertension may be increased circulating catecholamines resulting from a chronically increased sympathetic drive brought about by attempting to remain awake, as suggested by studies of the infl uence of posture in preserving alertness. 9, 10 ES and hypoxia both play a role in the cognitive impairment experienced by patients with OSA; however, a study comparing cognitive impairment in patients with chronic obstructive pulmonary disease (who experience hypoxia but not ES) and patients with OSA and ES (who experience both hypoxia and ES) showed that patients with OSA had poorer attention and vigilance, suggesting that the cognitive defi cits in OSA may be due to ES. 11 Cognitive impairment and falling asleep as a result of ES are thought to be responsible for a large proportion of the motor vehicle crashes that occur in patients with OSA. [12] [13] [14] [15] [16] In addition, cognitive impairment as a result of ES in the absence of falling asleep has been shown to impair the fl ight performance of sleep-deprived military pilots 17, 18 and to impair driving performance. 19 Furthermore, ES as a result of sleep deprivation, circadian rhythm misalignment, or OSA has been cited as a causative factor in a number of air and train crashes. 1, [20] [21] [22] Having both ES and snoring doubles an individual's risk of experiencing an occupational accident compared with those who have either of these conditions in isolation. 23 In addition to its detrimental effects on patient health, ES may impinge on activities of daily living. A study by Sforza and colleagues 24 reported that ES contributed more signifi cantly to impairment in all domains of the Medical Outcomes Study Short-Form (36-item) Health Survey (SF-36) than sleep-disordered breathing. ES may also lead to unemployment, relationship issues, reduced social interaction, and poor performance at work, school, or college. 25 For example, Mulgrew and colleagues 26 demonstrated that patients with ES experience signifi cant limitations at work in terms of time management (p Ͻ 0.001), mentalinterpersonal relationships (p Ͻ 0.001), and work output (p Ͻ 0.001).
There are two main objective measures of ES employed by sleep clinicians: the Multiple Sleep Latency Test (MSLT) and the Maintenance of Wakefulness Test (MWT). The MSLT consists of four or fi ve 20-minute nap opportunities spaced 2 hours apart and measures the duration from the start of the nap period to the fi rst signs of sleep in the patient. 27 The MWT also consists of multiple 20-to 40 -minute potential nap opportunities spaced over the course of a day and is performed in a darkened room in a semi-reclining position. 28 While the MSLT assesses the patient's ability to fall asleep, the MWT conversely assesses their ability to stay awake. Sleep latency is judged to be the period from the beginning of the test to the fi rst of three consecutive epochs of stage 1 sleep or one epoch of any other sleep stage. Conventionally, the onset of sleep during laboratory-based evaluations of ES is assessed using an electroencephalogram, left and right eye electro-oculograms, a mental/submental electromyogram, and an electrocardiogram.
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ES can also be assessed subjectively using the Epworth Sleepiness Scale (ESS), the Karolinska Sleepiness Scale (KSS), and the Stanford Sleepiness Scale (SSS). [29] [30] [31] The ESS is the most commonly used scale as it is a simple self-report test that can be fi nished in as little as 2 minutes. The patient completes a set of questions regarding their perceived ES in a series of situations such as sitting and reading or talking with friends. Total scores range from 0 to 24, with a score of Ն10 being indicative of ES. 31 As the ESS allows a patient to recall ES that has occurred over a number of preceding weeks, it is perceived to give a more accurate diagnosis than the KSS and SSS, which only allow assessment of ES at a single point in time. 32 Armodafinil is the R-enantiomer of the established wakefulness-promoting agent modafi nil, which is a racemic mixture of the R-and S-enantiomers. 33 The half-life of R-modafi nil is three times longer than that of S-modafinil (14 hours versus 3-4 hours, respectively). [34] [35] [36] Patients receiving chronic treatment with racemic modafi nil have threefold higher circulating levels of R-modafi nil than of S-modafi nil. 34, 35 The prolonged circulation of R-modafi nil may mean that the majority of effects attributed to modafi nil are due to R-modafi nil; this hypothesis resulted in further investigation of R-modafi nil (armodafi nil) in patients with a variety of disorders. [37] [38] [39] Further to this, armodafi nil was approved by the Food and Drug Administration in June 2007 for the improvement of wakefulness in patients with ES as a result of OSA, narcolepsy, and SWD. 
Pharmacology
The chemical names for armodafinil are 2-[(R)-(diphenylmethyl)sulfinyl]acetamide and 2-(R-benzhydryl-sulfi nyl)acetamide. 33 The chemical structure of armodafi nil is shown in Figure 1 . At the time of publication, armodafi nil is not yet marketed in the USA; however tablets containing armodafi nil 50, 150, or 250 mg have been approved by the FDA. Patients with narcolepsy or OSA are usually prescribed armodafi nil 150-250 mg each morning, while patients with SWD take armodafi nil 150 mg 1 hour before the start of their shift.
Pharmacodynamics
As armodafi nil is an enantiomer of modafi nil, much of the following information has been extrapolated from data concerning modafinil. The exact mechanism of action of armodafi nil is unknown, although modafi nil has some effect on dopaminergic, noradrenergic, and serotonergic receptors. [40] [41] [42] However, these effects are not well characterized and although ex vivo assays have shown that armodafi nil binds to the dopamine transporter and inhibits dopamine reuptake, resulting in increased extracellular dopamine levels in some animal brain regions, armodafi nil is not a direct nor an indirect dopamine receptor agonist. 33 Modafi nil is known to promote activation of the central nervous system via the hypothalamus, prefrontal cortex, and the anterior cingulate cortex. 43, 44 Hypocretin (also referred to as orexin) is a neuropeptide that is thought to prevent inappropriate changes in consciousness. 45, 46 Hypocretin-producing neurons are located within the hypothalamus and project into different brain regions. It is theorized that modafi nil activates these neurons to release dopamine and norepinephrine to promote wakefulness and may also inhibit reuptake of these neurochemicals. 47, 48 However, research in a hypocretinnull mouse model has indicated that the presence of hypocretin is not required for modafi nil to have wakefulness-promoting effects. 49 There are further clues to the mechanism of action of armodafi nil through research conducted with modafi nil. For example, haloperidol and α-methyl-p-tyrosine antagonize the effects of amphetamines but do not block the effects of modafinil, indicating that armodafi nil has a different mechanism of action to these drugs. 50 In addition, recent work in rats has indicated that modafi nil promotes arousal by increasing electrical coupling at gap junctions. 51, 52 The metabolites of armodafi nil-modafi nil sulfone and R-modafi nil acid-do not contribute to its wakefulness-promoting effects. 33 It appears that additional work is required before the mechanism of action of modafi nil and armodafi nil is completely elucidated.
Pharmacokinetics
The pharmacokinetics of armodafi nil have been characterized in a pooled analysis of three separate randomized studies. In total, 119 healthy subjects received single or multiple doses of armodafi nil 50 to 400 mg once daily for up to 14 days. 53 In addition, the pharmacokinetics of armodafi nil and modafi nil have been compared directly in a singledose study of healthy male volunteers undergoing acute sleep loss. 54 During this 2-day laboratory assessment, male volunteers aged 18-40 years with stable sleep/wake schedules were randomized to receive 100 mg (n = 18), 150 mg (n = 18), 200 mg (n = 17), or 300 mg (n = 18) of armodafi nil, 200 mg of modafi nil (n = 18), or placebo (n = 18) in the evening and were then prevented from sleeping until 1100 hours the next day. MWT assessments, blood samples, and psychomotor vigilance tasks were performed during the night. The pharmacokinetic parameters of armodafi nil and modafi nil given to healthy individuals in the postprandial state are shown in Table 1 .
Systemic exposure to armodafinil was proportional to its concentration at administration and no changes in kinetics were observed when this agent was administered at doses ranging from 50 to 400 mg over a 12-week period. 53 With chronic administration of armodafi nil, steady state was reached within 7 days. 53 On Day 7 and Day 14 of chronic administration, systemic exposure to armodafinil was 1.8 and 1.7 times higher, respectively, than achieved with single doses. 53 After single or multiple doses of armodafi nil, the pharmacokinetics of its metabolite R-modafi nil acid paralleled those of the parent compound but at approximately tenfold lower concentrations. The time (t max ) to attain peak plasma concentration (C max ) and the apparent terminal half-life of R-modafinil acid were similar to that of armodafi nil. 53 Concentrations of modafi nil sulfone were approximately 33% and 56% of that of the parent drug after single-dose and multiple-dose administration, respectively. The terminal half-life of modafi nil sulfone was considerably longer on Day 14 than that of armodafi nil (39 hours versus 17 hours, respectively). 53 The t max of armodafi nil 200 mg was 3-4 hours later than that for modafi nil 200 mg and the decline from C max was slower for the R-enantiomer. 54 These differences between armodafi nil and modafi nil are due to the presence of the short-lived S-enantiomer in the racemic compound, which means that the C max for modafi nil would need to be substantially higher than that of armodafi nil in order to maintain comparable late-day exposure. 54 
Absorption
Oral armodafinil is readily absorbed, with C max being achieved in approximately 2 hours, although, as shown in Table 1 , this may be delayed by 2-4 hours if armodafi nil is taken with food. 53, 54 Food has no effect on the overall bioavailability of armodafi nil when compared with the fasting state. The absolute oral bioavailability of armodafi nil has not been determined due to its aqueous insolubility, which precludes intravenous administration. 33 
Distribution
Armodafi nil has an apparent volume distribution of approximately 42 L after single doses and 47 L after 14 days' administration. 53 As these values are approximately equal to the estimated total water content of the human body, the volume distribution of armodafi nil indicates that this wakefulnesspromoting agent is widely distributed outside the vasculature but does not have a high affi nity for tissues. 53 It is unlikely that armodafi nil interacts with highly protein-bound drugs, although it does bind moderately with albumin. 
Metabolism
Armodafi nil undergoes hydrolytic deamidation, S-oxidation, and aromatic ring hydroxylation, with subsequent glucuronide conjugation of the hydroxylated products. As amide hydrolysis is a noncytochrome P450 (CYP)-related pathway, the pharmacokinetic profi le of armodafi nil is unlikely to be affected by medications that are metabolized by or interact with the CYP enzymes. 33 However, the pharmacokinetic profi le of armodafi nil may mean that this wakefulness-promoting agent affects medications that are metabolized by or interact with the CYP1A2, CYP219, or CYP3A4/5 enzymes.
Elimination
Modafinil data indicate that elimination of armodafinil may occur predominantly through metabolism in the liver, with Ͻ10% of the parent compound excreted in the urine. 33 After oral administration, armodafi nil exhibits an apparent monoexponential decline from its peak plasma concentration with an apparent terminal half-life of approximately 15 hours. 53 By contrast, the presence of the short-lived S-enantiomer in the racemic compound results in a biphasic decline in modafinil plasma concentrations. 35, 36 The oral clearance of armodafi nil is reported to be 39 mL/ min after a single dose and 33 mL/min after repeated administration for 14 days. 33, 53 Oral clearance of modafinil was reported to be reduced (∼20%) in two studies of elderly patients (mean age 63 years and 82 years). This fi nding may be in part due to the effects of aging but may also be attributed to the number of concomitant medications taken by elderly patients. As these results indicate that clearance of modafi nil is reduced in the elderly, it is likely that this will also be the case with armodafi nil. 33 The pharmacokinetics of armodafi nil were not signifi cantly altered in patients with chronic renal failure; however, in the presence of hepatic impairment, modafi nil clearance was decreased by about 60% and steady-state concentrations were doubled. Therefore, until the pharmacokinetics of armodafi nil are better characterized in this regard, armodafi nil should be used at reduced doses in patients with severe hepatic impairment. 33 
Drug-drug interaction profi le
The drug-drug interaction profi le of armodafi nil has been reported recently in a study of healthy subjects that based its selection of specifi c probe substrates on the known in vivo and in vitro drug profi le of modafi nil. 55 CYP enzymes are membranebound proteins that catalyze the metabolism of multiple substrates. For example, CYP3A4 metabolizes, among other substrates, benzodiazepines and immunosuppressants, while CYP2C19 metabolizes proton pump inhibitors and antiepileptic drugs. 56 Modafi nil has been shown to have the potential to induce CYP1A2, CYP3A4, and CYP2B6, to suppress CYP2C9, and to inhibit CYP2C19. 57, 58 In common with modafinil, armodafi nil moderately induced CYP3A4 activity in the intestine and liver, as shown by reductions in systemic exposure to oral and intravenous midazolam (by 32% and 17%, respectively) and increased systemic exposure to 1′-hydroxymidazolam following prolonged administration of armodafi nil. Armodafi nil also moderately inhibited CYP2C19 activity, as indicated by decreased area under the concentration versus time curve and C max values for the principal metabolite of omeprazole -5′-hydroxyomeprazole -and increases in the median ratio of omeprazole: 5′-hydroxyomeprazole after administration of armodafi nil. Unlike modafi nil, armodafi nil was shown not to affect CYP1A2 activity, as it had little effect on the t max and total oral clearance of caffeine and did not change systemic exposure to caffeine in healthy subjects. 55 Data from studies of modafi nil indicate that steroidal contraceptives may have reduced effectiveness when used with this wakefulness-promoting agent and for 1 month after its discontinuation. Patients should thus be advised to use alternative or additional methods of contraception when taking armodafinil. 59 Similarly, blood levels of the immunosuppressant drug ciclosporin may be reduced when used with armodafi nil. Monitoring of circulating ciclosporin concentrations and appropriate dose adjustment for ciclosporin should therefore be considered when these drugs are used concomitantly. 33 
Summary of pharmacologic fi ndings
Armodafi nil is the R-enantiomer of modafi nil. Both armodafinil and modafinil are wakefulnesspromoting agents with an unknown mechanism of action, although it is thought that modafi nil may produce its effects via the hypocretin system through dopamine-and/or norepinephrine-related pathways, or by increasing electrical coupling at gap junctions. 47, 48, 51, 52 Armodafi nil achieves its C max within approximately 2 hours in the fasted state and 4-6 hours in the postprandial state. 53, 54 The t max of armodafi nil is 3-4 hours later than that of modafi nil, meaning that it may have prolonged wakefulness-promoting effects later in the day than modafi nil. 54 Armodafi nil appears to be widely distributed in the body, does not have a high affi nity for tissues, and is unlikely to interact with highly protein-bound drugs. 33, 53 Armodafi nil is metabolized by amide hydrolysis, a CYP450-independent pathway, and is therefore unlikely to be affected by medication that interacts with CYP enzymes. 33 Armodafi nil has been shown to induce CYP3A4 activity and moderately inhibit CYP2C19. 55 This wakefulness-promoting agent is thought to be eliminated predominantly by the liver and demonstrates a monoexponential decline from its C max with a terminal half-life of approximately 15 hours.
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Effi cacy Preclinical
Armodafinil 100 mg/kg was found to have equivalent wakefulness-promoting effects to D-amphetamine 1 mg/kg when injected intraperitoneally into rats. 60 Armodafi nil 100 mg/kg and D-amphetamine 1 mg/kg both increased latency to the onset of consolidated sleep in rats. However, intraperitoneal injection of D-amphetamine 1 mg/ kg resulted in rebound hypersomnolence, as indicated by decreases in brief awakenings from sleep and increases in both nonrapid eye movement sleep (NREMS) as a percentage of total sleep time and NREMS bout duration. These changes are characteristic of sleep deprivation and were not experienced by the rats administered armodafi nil 100 mg/kg or 300 mg/kg in this study. 60 Furthermore, while D-amphetamine increased body temperature and the intensity of locomotor activity during wake periods, armodafi nil 100 mg/kg did not signifi cantly affect physiologic or behavioral parameters compared with a sterile methylcellulose vehicle placebo in the animals assessed. 60 Armodafinil administered at a high dose (300 mg/kg) had greater wakefulness-promoting effects than D-amphetamine and did not increase locomotor activity; however, this higher dose of armodafi nil did result in a statistically signifi cant decrease in body temperature (p Ͻ 0.001) compared with the methylcellulose vehicle. 60 Administration of armodafi nil at a low dose (30 mg/kg) resulted in significantly increased locomotor activity (p = 0.002) and significantly increased body temperature (p = 0.006) compared with the vehicle solution. 60 
Clinical
The effi cacy of armodafi nil in combating ES has been assessed in one single-dose study in healthy subjects and in four 12-week randomized, placebocontrolled clinical trials-one study in patients with SWD, one study in patients with narcolepsy, and two studies in patients with residual ES associated with OSA. [37] [38] [39] [61] [62] [63] A summary of the results of these clinical trials is given in Tables 2 and 3 . In addition, there are two ongoing open-label trials of armodafi nil: one in trial-naïve patients (with narcolepsy, OSA, or SWD) and one extension study in patients who completed any of the randomized trials and were able to participate for 12 months or longer.
Healthy subjects
In a single-dose study of healthy males, subjects were required to stay awake between 0700 hours on Day 1 and 1100 hours on Day 2. 54 Armodafi nil 100 mg, 150 mg, 200 mg, and 300 mg, or modafi nil 200 mg were given to subjects at 1925 hours; subjects were then assessed using six 20-minute MWT assessments conducted every 2 hours between 2200 hours on Day 1 and 0800 hours on Day 2. Armodafi nil and modafi nil signifi cantly improved wakefulness compared with placebo (mean wake time for the doses listed above was 16.1 minutes, 16.8 minutes, 18.5 minutes, 18.5 minutes, and 16.4 minutes, respectively, versus 10.5 minutes for placebo; p Ͻ 0.0001). 54 Armodafinil and modafinil also significantly improved sustained attention performance (measured using the Psychomotor Vigilance Test) compared with placebo in healthy subjects, with fewer lapses of attention and shorter median reaction times during the period of enforced sleep loss (p Ͻ 0.0001 for both drugs).
Although armodafi nil and modafi nil required 5-6 hours and 2 hours, respectively, to reach t max , both agents demonstrated signifi cant wakefulnesspromoting effects compared with placebo at the earliest recorded timepoint (2200 hours, i.e, approximately 2.5 hours after drug administration). However, when the effects of armodafi nil 200 mg and modafi nil 200 mg were compared, MWT sleep latencies were numerically longer and lapses in attention were numerically fewer for subjects receiving armodafi nil. The differences between the compounds were evident from 6 hours after administration, with the greater effects of armodafi nil lasting for up to 13.5 hours. On Day 2 of the study (during recovery sleep following sleep loss), decreases in sleep effi ciency were observed in subjects who had received the higher doses of armodafi nil (p Ͻ 0.01 versus pretreatment values). 54 
Narcolepsy
Hypocretins are neuropeptides that are thought to prevent inappropriate fl uctuations between states of consciousness. Abnormalities in the hypocretin system-particularly loss of the neurons that produce hypocretins in the hypothalamus-are a defi ning feature of narcolepsy with cataplexy (sudden loss of muscle tone). 64, 65 Narcolepsy is universally characterized by ES; however, cataplexy is found in only 60%-70% of patients with narcolepsy. 66, 67 The prevalence of narcolepsy with cataplexy is estimated to be 0.02%-0.05%, while the incidence of this disorder is thought to be 0.74 per 100 000 person-years. 68 There is currently no cure for narcolepsy, instead treatment focuses on addressing the symptoms of ES and cataplexy. A 12-week, randomized, doubleblind, placebo-controlled trial of armodafinil 150 mg or 250 mg once daily in the treatment of ES associated with narcolepsy was conducted in 47 centers located across the USA, Canada, France, Australia, Germany, and Russia. 37 Patients with or without cataplexy were permitted to enroll in the study provided that they were on a stable dose of anticataplectic medicine and were not taking sodium oxybate; patients were excluded if they were receiving melatonin or sedatives such as barbiturates, benzodiazepines, and zolpidem. Patients were randomized to receive armodafi nil 150 mg (n = 64), 250 mg (n = 67), or placebo (n = 63). The primary endpoint of this study was change in mean sleep latency, assessed using the MWT between 0900 and 1500 hours, and the proportion of patients demonstrating improvements on the Clinical Global Impression of Change scale (CGI-C). Study medication was taken by patients At the fi nal visit (Week 12 of the study or the last scheduled clinic visit before discontinuation) treatment differences in sleep latency between 0900 and 1500 hours relative to placebo were 3.2, 4.5, and 3.8 minutes for the 150 mg and 250 mg groups and for both treatment groups combined, respectively (p Ͻ 0.001 for all comparisons). Sleep latency relative to placebo was also improved when measured later in the day. Between 1500 and 1900 hours, treatment differences relative to placebo were 2.7, 2.8, and 2.8 minutes in the 150 mg, 250 mg, and armodafi nil combined groups, respectively (p Ͻ 0.05 for the combined group and the 150 mg group versus placebo). At the fi nal visit, the proportion of patients who were judged by the study investigators to have experienced at least minimal improvement in their CGI-C ratings was signifi cantly higher in all activetreatment groups compared with placebo (p Ͻ 0.001). In patients receiving armodafi nil, attention (p Ͻ 0.05 for the 150 mg group and the combined group) and episodic secondary memory (p Ͻ 0.05 for all groups) were also signifi cantly improved at the fi nal visit compared with those receiving placebo. Night-time sleep was not affected in patients administered armodafi nil. 37 Obstructive sleep apnea OSA is a sleep disorder characterized by episodes of partial or complete collapse of the airway and is associated with increased morbidity and mortality. 69 The most common symptom of OSA is ES. Approximately 2% and 4% of men and women, respectively, in the USA have OSA with ES. 70 Current evidence indicates that up to 93% of women and 82% of men with moderate to severe OSA remain undiagnosed. 71 OSA is most commonly treated using a continuous positive airway pressure (CPAP) device, which maintains an open airway during sleep. Dental devices and surgery are also indicated for the treatment of patients with OSA. 72 ES persists in 22% and 52% of patients with OSA assessed using the ESS or MSLT, respectively, even after treatment with CPAP. 73 Armodafi nil 150 mg or 250 mg once daily is indicated as an adjunctive pharmacotherapy to CPAP or other forms of treatment for OSA in order to reduce ES, although it is important that patients are counseled to remain compliant with their primary treatment modality. Roth and colleagues 39 have studied the effi cacy of armodafi nil for ES associated with OSA in a 12-week, double-blind, randomized, placebo-controlled trial conducted in 37 centers across the USA and Canada. Patients aged 18-65 years with moderate OSA and residual ES despite Ն4 weeks of adequate CPAP treatment were randomized to take armodafinil 150 mg (n = 133), 250 mg (n = 131), or placebo (n = 131) once daily before 0800 hours, approximately 30 minutes before breakfast. The primary endpoints of this study were the change from baseline to Week 12 (or discontinuation) in mean sleep latency across the fi rst four 30-minute MWT assessments performed each day (at 0900, 1100, 1300, and 1500 hours) and the rate of at least minimal improvement in the CGI-C. At the fi nal visit, patients administered armodafi nil (150 mg, 250 mg, and both treatment groups combined) demonstrated significant increases from baseline in sleep latency across the fi rst four MWT assessments performed each day compared with the placebo group (p Ͻ 0.001). Signifi cant changes were seen as early as Week 4, when patients in the armodafi nil 150 mg and the combined groups experienced statistically significant mean changes from baseline in sleep latency across the last three MWT assessments of each day (at 1500, 1700, and 1900 hours) compared with placebo (p = 0.01 and p Ͻ 0.01, respectively). MWT results are shown in Figures 2A and 2B . At all timepoints, the proportion of patients with at least minimal improvement on the CGI-C was significantly greater in the armodafi nil-treated group than in the placebo group (p Ͻ 0.001) (Figure 3 ). 39 Hirshkowitz and colleagues 62 also performed a 12-week, randomized, double-blind, placebocontrolled, parallel-group study of patients with at least moderate OSA and residual ES despite adequate CPAP treatment. This study took place in 36 centers across the USA, Australia, Russia, Germany, and France and randomized 131 patients to the armodafi nil 150 mg arm and 132 patients to the placebo arm. The primary endpoints of this study were improvements from baseline in sleep latency at the fi rst four MWT tests (0900, 1100, 1300, and 1500 hours) and improvements in clinical condition assessed using the CGI-C. Armodafi nil signifi cantly improved wakefulness compared with placebo at all assessment visits. At the fi nal visit, sleep latency across the fi rst four MWT assessments performed was signifi cantly higher in the armodafi nil group compared with placebo (+2.3 minutes versus placebo −1.3 minutes; p = 0.0003). At the fi nal visit, sleep latency in the last three MWT assessments (performed at 1500, 1700, and 1900 hours) was also signifi cantly increased in the armodafi nil-treated patients compared with placebo (+1.8 minutes versus −0.5 minutes, respectively; p = 0.0435). At the fi nal visit, the proportion of patients with at least minimal improvement in their clinical condition was signifi cantly higher in the armodafi nil group compared with the placebo group (71% versus 53%; p = 0.0069). In addition, episodic secondary memory was signifi cantly improved at the fi nal visit in patients taking armodafi nil (p = 0.0102 versus placebo). 62 Pooled analyses of the results of these two studies 63 demonstrated that at the fi nal visit, sleep latency was increased by 2.0 minutes with armodafi nil versus a decrease of 1.5 minutes for placebo (p Ͻ 0.0001). Furthermore, patients treated with armodafi nil had improved wakefulness later in the day (at the last three MWT assessments at 1500, 1700, and 1900 hours) compared with placebo (+1.1 minutes versus −0.3 minutes, respectively; p Ͻ 0.05). The quality of secondary episodic memory was also signifi cantly improved with armodafinil (p Ͻ 0.05 versus placebo). Armodafi nil treatment did not adversely affect night-time sleep in either of the 12-week studies as assessed by polysomnography. Although CPAP use did decline during the study (−0.3 hours versus −0.1 hours for armodafi nil and placebo, respectively; p Ͻ 0.0001), this was not accompanied by an increase in the number of apneas or hypopneas (breathing interruptions) experienced by the study participants. 63 
Shift-work disorder
The circadian rhythm disorder SWD is caused by enforcing an artifi cial pattern of sleep and wake that is misaligned with the body's internal circadian rhythm; the most obvious example of this is the nightshift, which requires workers to stay awake at night and sleep during the day. Not all shift workers develop SWD; those who do experience insomnia when attempting to sleep and ES during work hours. 74 Currently, the true prevalence of SWD is yet to be elucidated. The chronic strain of shift work in addition to sleep debt and circadian misalignment is thought to be responsible for the increased risk of cardiovascular disease seen in patients with SWD and their increased risk of peptic ulcers and mood disorders, such as irritability and depression. 74, 75 Furthermore, patients with SWD are more likely to miss work and social activities than symptom-free daytime workers. 75 To date, the single study of armodafi nil in this indication has been reported in two abstracts. The study assessed armodafi nil 150 mg in the treatment of ES associated with SWD in a 12-week, doubleblind, placebo-controlled, randomized study of 216 permanent-or rotating-shift workers. 38, 61 Study participants took armodafi nil or placebo only on the nights when they worked a night shift or when they were assessed in a simulated night shift in the laboratory (at Weeks 4, 8, and 12). The primary endpoints of this study were sleep latency and clinical condition assessed using the MSLT and Clinical Global Impression of Improvement (CGI-I), respectively. At the fi nal visit, patients administered armodafi nil experienced signifi cant increases in sleep latency compared with the placebo group (3.1 minutes versus 0.4 minutes, respectively; p Ͻ 0.0001). Furthermore, CGI-I ratings were improved in a signifi cantly greater proportion of patients in the armodafi nil group than in the placebo group (75% versus 59%, respectively; p = 0.001). Armodafi nil also signifi cantly improved attention and episodic secondary memory relative to placebo (p Ͻ 0.05) and patients taking armodafi nil in this trial reported that the study medication did not affect their ability to sleep during the daytime.
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Summary of effi cacy data
In a preclinical study in rats, armodafinil had equivalent wakefulness-promoting effects to D-amphetamine, without leading to symptoms characteristic of sleep deprivation. 60 Both modafi nil and armodafi nil have been reported to demonstrate signifi cant wakefulness-promoting effects compared with placebo in sleep-deprived healthy subjects; however, armodafi nil also demonstrated numerically longer increases in sleep latency and numerically fewer lapses in attention compared with modafi nil in this study. The effects of armodafi nil lasted for up to 13.5 hours in healthy subjects. Armodafi nil signifi cantly increased sleep latency compared with placebo in patients with narcolepsy, SWD, and treatment-resistant ES associated with OSA and also signifi cantly improved patients' clinical condition, as assessed using the CGI-C or CGI-I. In addition, armodafi nil increased attention and secondary episodic memory compared with placebo in patients with narcolepsy or SWD and improved secondary episodic memory in patients with ES associated with OSA.
37-39,61-63
Safety and Tolerability
Armodafinil is generally well tolerated, with headache being the most common adverse event associated with use of this medication. In a single-dose pharmacokinetics study in healthy subjects, abdominal pain and nausea were reported in 13% of subjects administered armodafi nil and the incidences of headache and nausea increased in the higher dose (200 mg and 300 mg) groups. 54 Pooled safety data from 14-day pharmacokinetics studies of armodafi nil indicated that armodafi nil 400 mg daily appeared to be an intolerable dose and therefore this regimen was discontinued after 7 days.
Headache, nausea, dizziness, and decreased appetite were the most commonly reported adverse events in a 12-week randomized trial of armodafi nil in patients with narcolepsy. 37 These events were usually mild to moderate in severity and occurred with greatest frequency during the fi rst 2 weeks of the study. In the study of patients with narcolepsy, one serious adverse event of severe acute urticaria and angioedema was reported in the armodafi nil 150 mg group; however, owing to the patient's history, this event was judged by the study investigator to be unlikely to be related to treatment with armodafi nil. In addition, analysis of armodafi nil combined data showed a small but statistically significant increase in blood pressure relative to placebo (0.4 mmHg versus −2.6 mmHg, respectively; p = 0.0294). 37 Headache, nausea, nasopharyngitis, and anxiety were the most common adverse events in a 12-week study of armodafi nil in patients with SWD. 38 In a 12-week study of armodafi nil in patients with ES despite CPAP treatment for OSA, the most frequent adverse event was headache, which was reported in 17.6% (46/262) of patients versus 8.5% (11/130) of patients who received placebo. 39 Most adverse events were of mild to moderate severity. Liver function tests showed that mean changes from baseline in γ-glutamyl transpeptidase and alkaline phosphatase concentrations were statistically signifi cantly higher in armodafi nil-treated patients versus placebo (p Ͻ 0.01 and p Ͻ 0.001, respectively) but these changes were not considered to be clinically meaningful. When compared with placebo, armodafi nil-treated patients experienced small increases from baseline in morning diastolic blood pressure (armodafi nil +0.6 mmHg versus placebo −1.4 mmHg; p Ͻ 0.05) and evening heart rate (armodafi nil +1.2 bpm versus placebo −1.2 bpm; p Ͻ 0.05). A study by Hirshkowitz and co-workers 62 in the same indication (residual ES associated with OSA) again reported that headache was the most common adverse event associated with armodafi nil treatment, followed by nausea, diarrhea, dizziness, and anxiety (Ն5% of patients). Adverse events were generally mild to moderate in severity and no clinically meaningful changes in laboratory measures, vital signs, or results of physical examinations were reported. 62 The safety and tolerability data reported in a pooled analysis 63 of the studies by Hirshkowitz and colleagues 62 and Roth and colleagues 39 are shown in Table 4 . These data indicate that, in addition to the aforementioned headache, nausea, dizziness, and anxiety, insomnia is experienced by Ն5% of patients receiving armodafinil (6% versus 1% for patients given placebo). As reported in clinical trials of modafi nil, insomnia may indicate that the medication was taken too close to bedtime, or in too high a dose. In the event that a patient experiences insomnia with armodafi nil, dose reduction is recommended. 33 Armodafi nil is contraindicated in patients with known hypersensitivity to modafi nil and armodafi nil or its inactive ingredients. Serious rash, including Stevens-Johnson syndrome, has been reported in patients receiving modafi nil. While no serious skin rashes have been reported in clinical trials of armodafi nil, a similar risk of serious rash with armodafi nil cannot be ruled out.
Controlled trial data for armodafi nil have shown that psychiatric events, such as anxiety, agitation, nervousness, and irritability, led to treatment discontinuation more frequently than in patients given placebo (1.2% versus 0.3%, respectively). 33 In addition, a number of psychiatric adverse events, including mania, delusions, and hallucinations, have been reported for modafi nil in postmarketing surveillance data. The possibility that the same psychiatric events may occur cannot be ruled out for armodafi nil.
Abuse potential with modafi nil is low and thus may also be low with armodafi nil. 76 Conversely, other treatments for ES, such as amphetamines or sodium oxybate, have a high abuse potential or a high likelihood of misuse. 77 For these reasons, armodafi nil is a Schedule IV medication while amphetamines and sodium oxybate are Schedule II and III medications, respectively.
Summary of safety and tolerability
Armodafi nil was generally well tolerated in clinical trials; headache, nausea, dizziness, decreased appetite, anxiety, and insomnia of mild to moderate severity were the most commonly reported adverse events. 33, 63 Statistically significant changes in blood pressure and liver function tests have been observed in armodafi nil-treated patients, but were judged not to be clinically meaningful. 33 Although serious rash and psychiatric adverse events have not been reported for patients given armodafi nil, these events have been observed in modafinil-treated patients; therefore, use of armodafi nil is contraindicated in patients who are likely to be susceptible to such events. 33 Abuse potential with armodafi nil is likely to be of a similar low level to that of modafi nil and both agents are therefore Schedule IV medications. Patients administered armodafinil in a trial assessing the effi cacy of this wakefulness-promoting agent in the treatment of ES associated with narcolepsy were given electronic diaries and were also questioned using the ESS. 37 Patients administered armodafinil 150 mg or 250 mg recorded that they experienced 33% and 44% reductions in the number of unintended daily sleep episodes, respectively; patients given placebo experienced a 10% reduction in such sleep episodes (p Ͻ 0.0001). In addition, daily naps were reduced by 41%, 44%, and 22% for patients who received armodafi nil 150 mg, 250 mg, or placebo, respectively (p = 0.0039 for overall treatment effect). Moreover, at the final visit, 21% and 28% of patients in the armodafi nil 150 mg and 250 mg groups had an ESS score Ͻ10 (indicative of normal alertness) compared with 7% of patients in the placebo group (p = 0.0312 and p = 0.0023, respectively). Global fatigue-assessed using the Brief Fatigue Inventory-was also signifi cantly improved in all treatment groups versus placebo at the fi nal visit (p Ͻ 0.01 for all groups).
Diary data, ESS scores, and Brief Fatigue Inventory scores from patients enrolled in the two 12-week studies of armodafi nil for residual ES associated with OSA reported that armodafi nil reduced both fatigue and ES. 39, 62, 63 The occurrence of unintended sleep episodes and daily naps was signifi cantly reduced in the armodafi nil-treated patients versus placebo 39, 62 ( Figures 4A and 4B ) and reductions in subjective ES were signifi cantly greater in the armodafinil groups at all visits (Weeks 4, 8, and 12) compared with placebo (p Ͻ 0.01). 39, 62 Furthermore, at the fi nal visit, armodafi nil signifi cantly reduced global fatigue and worst fatigue in the last 24 hours compared with placebo (p Ͻ 0.05). 39, 63 Average fatigue scores were signifi cantly reduced following treatment with armodafi nil 150 mg or 250 mg compared with placebo (p Ͻ 0.01). 63 Electronic diaries and the KSS were used in a trial of armodafi nil in the treatment of ES associated with SWD, 38 in which the wakefulness-promoting agent signifi cantly reduced the maximum level of ES experienced during night-shift work compared with placebo (1.1 versus 2.0 points, respectively; p Ͻ 0.0001). Compared with placebo, armodafi nil also significantly attenuated ES during the commute home (1.2 for placebo versus 0.6 points for armodafinil; p = 0.0027). Subjective ES measured using the KSS was reduced with armodafi nil relative to placebo (p Ͻ 0.005). 38 
Quality of life
Data concerning the effects of armodafi nil on patient quality of life are sparse and further studies are warranted. Based on available studies, quality of life would be improved by the reported reductions in fatigue and increases in episodic secondary memory in the trials of armodafi nil in patients with residual ES associated with OSA. 39, 62, 63 Rates of discontinuation in armodafi nil studies
In the study by Roth and colleagues 39 of armodafi nil in patients with residual ES associated with OSA despite adherence to CPAP treatment, 15% (40/264) of patients randomized to armodafi nil discontinued treatment compared with 8% (11/131) of patients administered placebo. The difference in the rates of discontinuation between the two study groups did not reach statistical signifi cance. A study of armodafi nil in the same indication reported similar results with 15% (20/131) of patients in the active-treatment group discontinuing treatment compared with 11% (14/132) of patients given placebo. 62 Noncompliance was the reason for discontinuation in 3 patients who received armodafi nil. 62 Overall, 7.5% (10/133) and 11.5% (15/131) of patients who received armodafi nil 150 mg and 250 mg, respectively, discontinued treatment due to adverse events versus 3.8% (5/131) of patients given placebo in a study of patients with SWD. 38 In a study of armodafinil in patients with narcolepsy, 25% and 16% of patients randomized to receive armodafinil 150 mg or 250 mg, respectively, withdrew from the study compared with 14% of patients in the placebo group. Adverse events and withdrawal of consent were the most common reasons for discontinuation in this study. 37 
Adherence and uptake
The benefi ts of modafi nil do not always persist beyond a few hours, meaning that some patients may require dose escalation or split dosing. The wakefulness-promoting effects of armodafi nil last longer than those of modafi nil (as indicated by its longer t max and presence at higher concentrations later in the day), which may facilitate once-daily dosing in patients receiving armodafi nil, a feature that is convenient for patients and which may aid with compliance. 54 As shown in the "Rates of discontinuation in armodafi nil studies" section, discontinuation rates in clinical trials of armodafi nil have been low; however, until armodafi nil becomes commercially available and postmarketing surveillance data can be gathered, any benefi ts of armodafi nil in terms of patient compliance remain theoretical.
Summary of patient-focused perspectives
Armodafi nil demonstrated signifi cant reductions in subjectively measured ES in clinical trials of patients with ES associated with narcolepsy, SWD, or OSA. [37] [38] [39] 62, 63 In addition, patients with ES associated with narcolepsy or OSA treated with armodafinil experienced significant reductions in the number of unintended daily sleep episodes and daily naps compared with patients given placebo. 37, 39, 62, 63 Fatigue scores were also signifi cantly reduced by armodafi nil in patients with ES associated with OSA. 39, 63 ES experienced during night-shift work and the consequent commute home was also signifi cantly reduced in patients with SWD given armodafi nil versus those given placebo. 38 These improvements in patient-reported outcomes alongside the increased attention and secondary episodic memory conferred by armodafinil 37, 38, 62, 63 are expected to improve patients' quality of life; however, data in this respect are sparse and further studies are required. Discontinuation rates were comparable for patients given armodafi nil or placebo in randomized clinical trials. Moreover, the prolonged wakefulnesspromoting effects of armodafi nil late in the day and once-daily dosing may improve convenience and increase patient compliance.
Conclusion and Place in Therapy
Armodafi nil has demonstrated its effi cacy as a wakefulness-promoting agent by increasing sleep latency and improving clinical condition in patients with ES associated with narcolepsy, SWD, and OSA. Furthermore, the effects of armodafi nil may persist longer than those of modafi nil, which could help patients stave off ES for longer. The possibility of once-daily dosing with armodafi nil may also aid in patient compliance (although modafi nil can also be given once daily in most patients). Armodafi nil also improves attention and episodic secondary memory in patients with ES associated with OSA and reduces fatigue across the spectrum of patients assessed and is consequently likely to improve their activities of daily living and quality of life. Armodafi nil was also well tolerated in these trials and most adverse events were mild to moderate in severity.
All of the trials conducted with armodafi nil to date have been of 12 weeks' duration and longer studies would assist in characterizing the long-term effi cacy of armodafi nil in patients with ES due to a variety of conditions. The results of the ongoing open-label trials are eagerly awaited for this reason. Furthermore, evaluations of armodafinil are planned for other indications, including bipolar depression, cognition deficits associated with schizophrenia, ES in Parkinson's disease, and fatigue in patients treated for cancer. 59 The author has observed that modafi nil is an effective countermeasure to ES in his own traumatic brain injury population and armodafi nil may also be of use in this indication. 78 In addition, armodafi nil has been shown to attenuate sleep deprivation in healthy subjects 54 and may therefore be of assistance to healthy individuals in extreme circumstances, for example in military applications where a high level of vigilance is required for extended periods. Modafi nil is approved by the U.S. Air Force for use by pilots during fl ights of long duration 79 and repeated doses of modafi nil given prophylactically have been shown to improve alertness and performance in a simulator test of sleep-deprived army helicopter pilots. 80 Using quantitative electroencephalography, one may measure brainwave frequencies, amplitudes, and densities. Delta brainwave activity (1-3 Hz) is a representative sleep characteristic, while alpha brainwave activity (8) (9) (10) (11) (12) in the posterior brain regions is a representative awake characteristic. Delta brainwave activity is increased and alpha brainwave activity is reduced in sleep-deprived individuals, 81 and repeated doses of modafi nil 100 mg have been shown to postpone the onset of these brainwave patterns for up to 42 hours and 46 hours, respectively, in healthy military aviators. 81 Train and truck drivers are also often required to work long and/or consecutive shifts carrying out tasks that may be repetitive or monotonous. [82] [83] [84] Armodafi nil may therefore be useful in promoting wakefulness in commercial/military aviators and drivers who are required to remain awake for long periods of time and further investigation into such matters is warranted.
In summary, armodafi nil is the potent R-isomer of modafi nil, with a longer duration of effectiveness than the racemic compound but with a similar tolerability and safety profile. It is currently approved as a wakefulness-promoting agent in patients with ES associated with OSA, narcolepsy, and SWD and has been shown to improve patient-reported outcomes in individuals with these conditions. Future potential applications may include ES associated with traumatic brain injury, chronic fatigue syndromes, hypersomnias, and other circadian rhythm disorders. Armodafi nil is likely to further reduce the disability associated with ES and improve quality of life beyond the level of improvement conferred by modafi nil in patients who are chronically drowsy.
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